SCHEMBL1047477

SCHEMBL1047477

Nc1ccc(N2CCN(C3CC3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
KMT2A Q03164 5/20 0.57
ALDH1A1 P00352 4/20 0.57
GFER P55789 4/20 0.57
L3MBTL1 Q9Y468 4/20 0.57
KDM4E B2RXH2 3/20 0.57
GAA P10253 3/20 0.57
LMNA P02545 3/20 0.57
HTT P42858 2/20 0.57
L3MBTL3 Q96JM7 2/20 0.57
MAPK1 P28482 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
ADRA2C P18825 1/20 0.57
PTK2B Q14289 1/20 0.57
ESR2 Q92731 1/20 0.57
MEN1 O00255 3/20 0.53
NPC1 O15118 1/20 0.53
USP2 O75604 1/20 0.53
TP53 P04637 1/20 0.53
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16764224 0.98 MAPT (0.57) MAPTKMT2AALDH1A1GFERL3MBTL1
SCHEMBL22466041 0.93 L3MBTL1 (0.59) MAPTKMT2AALDH1A1GFERL3MBTL1
SCHEMBL5743020 0.92 L3MBTL1 (0.58) MAPTKMT2AALDH1A1GFERL3MBTL1
SCHEMBL1045480 0.92 L3MBTL1 (0.58) MAPTKMT2AALDH1A1GFERL3MBTL1
SCHEMBL1044237 0.91 MAPT (0.58) MAPTKMT2AALDH1A1GFERL3MBTL1
SCHEMBL16195572 0.89 MAPT (0.50) MAPTKMT2AALDH1A1GFERL3MBTL1
SCHEMBL156523 0.88 MAPT (0.68) MAPTKMT2AALDH1A1GFERL3MBTL1
SCHEMBL17840369 0.88 ALDH1A1 (0.58) MAPTKMT2AALDH1A1GFERL3MBTL1
SCHEMBL16447995 0.85 MAPT (0.50) MAPTKMT2AALDH1A1GFERL3MBTL1
SCHEMBL2236451 0.85 L3MBTL3 (0.81) MAPTKMT2AALDH1A1GFERL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619407-A1 PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 Curadev Pharma Ltd (GB) 2025-09-24 EP disclosed
US-20250282794-A1 PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 CURADEV PHARMA LTD (GB) 2025-09-11 US disclosed
CN-119431239-A Compounds, pharmaceutical compositions, kits and uses thereof 密执安大学评议会 2025-02-14 CN disclosed
CN-113710241-B Substituted bicyclic and tetracyclic quinones and related methods of use 密执安大学评议会 2024-11-15 CN disclosed
EP-4427812-A2 SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE The Regents of the University of Michigan (US) 2024-09-11 EP disclosed
EP-3934634-B1 SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE UNIV MICHIGAN REGENTS (US) 2024-07-24 EP disclosed
WO-2024092255-A9 4-AMINOQUINOLINES FOR TREATMENT OF MULTIDRUG RESISTANT MALARIA THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2024-07-18 WO disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 US disclosed
US-20240182423-A1 4-AMINOQUINOLINES FOR TREATMENT OF MULTIDRUG RESISTANT MALARIA UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2024-06-06 US disclosed
CN-114025847-B Compounds and compositions as modulators of TLR signaling 神经孔疗法股份有限公司 2024-05-24 CN disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2007-11-01 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
CN-1738615-A Diaminotriazoles as inhibitors of protein kinases VERTEX PHARMA (US) 2006-02-22 CN disclosed
EP-1562589-A2 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2005-08-17 EP disclosed
US-20040214817-A1 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-10-28 US disclosed
WO-2004046120-A2 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282794-A1 PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 PDXK, PGK1, CMPK1 MAPT 4306/4885KMT2A 1914/4885ALDH1A1 1053/4885
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 MAPT 937/4885KMT2A 912/4885ALDH1A1 3235/4885
US-20040214817-A1 Diaminotriazoles useful as inhibitors of protein kinases MAP3K20, MAP3K1, MAP3K5 MAPT 937/4885KMT2A 912/4885ALDH1A1 3235/4885
US-20070254892-A1 Dihydropyrazolopyrimidinone derivatives WEE1, WEE2, GRK3 MAPT 4041/4885KMT2A 1433/4885ALDH1A1 755/4885
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B MAPT 3813/4885KMT2A 1422/4885ALDH1A1 3226/4885
US-20240182423-A1 4-AMINOQUINOLINES FOR TREATMENT OF MULTIDRUG RESISTANT MALARIA ABCC1, SLC11A2, SLC47A1 MAPT 1156/4885KMT2A 294/4885ALDH1A1 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.